INmune Bio Inc (INMB)
9.46
-0.08
(-0.79%)
USD |
NASDAQ |
May 31, 16:00
9.475
+0.02
(+0.16%)
After-Hours: 20:00
INmune Bio Enterprise Value: 168.59M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 168.59M |
| May 30, 2024 | 170.08M |
| May 29, 2024 | 172.35M |
| May 28, 2024 | 182.24M |
| May 24, 2024 | 181.45M |
| May 23, 2024 | 181.65M |
| May 22, 2024 | 193.12M |
| May 21, 2024 | 190.36M |
| May 20, 2024 | 203.61M |
| May 17, 2024 | 196.09M |
| May 16, 2024 | 202.42M |
| May 15, 2024 | 206.18M |
| May 14, 2024 | 188.97M |
| May 13, 2024 | 177.69M |
| May 10, 2024 | 179.67M |
| May 09, 2024 | 194.51M |
| May 08, 2024 | 188.55M |
| May 07, 2024 | 202.38M |
| May 06, 2024 | 202.78M |
| May 03, 2024 | 210.09M |
| May 02, 2024 | 201.39M |
| May 01, 2024 | 210.68M |
| April 30, 2024 | 215.42M |
| April 29, 2024 | 214.04M |
| April 26, 2024 | 193.42M |
| Date | Value |
|---|---|
| April 25, 2024 | 184.97M |
| April 24, 2024 | 180.84M |
| April 23, 2024 | 166.04M |
| April 22, 2024 | 174.86M |
| April 19, 2024 | 133.82M |
| April 18, 2024 | 141.64M |
| April 17, 2024 | 134.91M |
| April 16, 2024 | 148.01M |
| April 15, 2024 | 155.84M |
| April 12, 2024 | 170.58M |
| April 11, 2024 | 180.60M |
| April 10, 2024 | 176.04M |
| April 09, 2024 | 171.01M |
| April 08, 2024 | 167.42M |
| April 05, 2024 | 167.06M |
| April 04, 2024 | 165.45M |
| April 03, 2024 | 162.76M |
| April 02, 2024 | 178.01M |
| April 01, 2024 | 188.25M |
| March 31, 2024 | 192.37M |
| March 28, 2024 | 185.88M |
| March 27, 2024 | 183.72M |
| March 26, 2024 | 187.33M |
| March 25, 2024 | 184.28M |
| March 22, 2024 | 193.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
16.76M
Minimum
Mar 18 2020
471.72M
Maximum
Sep 07 2021
124.97M
Average
105.19M
Median
Oct 19 2023
Enterprise Value Benchmarks
| AVITA Medical Inc | 221.05M |
| Dare Bioscience Inc | 38.15M |
| Zevra Therapeutics Inc | 184.90M |
| Xeris Biopharma Holdings Inc | 475.90M |
| Kodiak Sciences Inc | -78.86M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.02M |
| Revenue (Quarterly) | 0.014M |
| Total Expenses (Quarterly) | 11.03M |
| EPS Diluted (Quarterly) | -0.61 |
| Profit Margin (Quarterly) | -78.75K% |
| Earnings Yield | -20.30% |
| Normalized Earnings Yield | -20.30 |